Ratings by Leerink (Faisal Khurshid)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/9/2026 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2025 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2025 | AbCellera Biologics | ABCL | Downgrade | Market Perform (Outperform) |
4.53 (6.52) |
43.93% | Details | |
| 10/10/2025 | Nurix | NRIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Market Perform (Outperform) |
6.03 (0.50) |
-91.71% | Details | |
| 9/12/2025 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
59.68 (129.89) |
117.64% | Details | |
| 8/21/2025 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2025 | Shattuck Labs | STTK | Maintain | Outperform (N/A) |
|
Details | ||
| 7/9/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2025 | AbCellera Biologics | ABCL | New Coverage | Outperform (N/A) |
3.80 (4.53) |
19.21% | Details | |
| 7/7/2025 | Rhythm Pharmaceuticals | RYTM | New Coverage | Outperform (N/A) |
65.77 (107.49) |
63.43% | Details | |
| 6/26/2025 | aTyr Pharma | ATYR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/25/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Nurix | NRIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/8/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
12.39 (93.73) |
656.5% | Details | |
| 3/17/2025 | Nurix | NRIX | New Coverage | Market Perform (N/A) |
13.59 (22.71) |
67.11% | Details | |
| 3/17/2025 | Shattuck Labs | STTK | New Coverage | Outperform (N/A) |
1.19 (6.43) |
440.34% | Details | |
| 2/18/2025 | aTyr Pharma | ATYR | New Coverage | Outperform (N/A) |
3.41 (6.03) |
76.83% | Details | |
| 12/16/2024 | PureTech Health | PRTC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2024 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | PureTech Health | PRTC | New Coverage | Outperform (N/A) |
20.36 (17.42) |
-14.44% | Details | |
| 9/9/2024 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
45.40 (110.40) |
143.17% | Details | |
| 3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Market Perform (Outperform) |
10.64 (21.55) |
102.54% | Details | |
| 5/23/2023 | Rain Therapeutics | RAIN | Downgrade | Market Perform (Outperform) |
9.93 (1.71) |
-82.78% | Details | |
| 3/21/2023 | Rain Therapeutics | RAIN | New Coverage | Outperform (N/A) |
7.77 (1.71) |
-77.99% | Details | |
| 11/30/2022 | Lantheus Holdings | LNTH | New Coverage | Outperform (N/A) |
60.65 (105.39) |
73.77% | Details |
